The efficacy of alogliptin and pioglitazone to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor

The efficacy of alogliptin and pioglitazone to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor - The efficacy of alogliptin and pioglitazone to gastrin and glycemic control

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015466

Enrollment

Registered

2014-10-20

Start date

2014-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes

Interventions

Alogliptin Pioglitazone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 diabetes whose HbA1c is >6.4% under life style intervention and ordinal dosage of SU or metformin or alpha-glucosidase inhibitor treatment

Exclusion criteria

Exclusion criteria: severe diabetic ketosis diabetic coma or past history of pre-coma severe infection before or after operation or serious traumatic injury past history of hypersensitivity or allergic reaction to alogliptin and pioglitazone heart failure and past history of heart failure pregnancy or possibilty of pregnancy

Design outcomes

Primary

Measure	Time frame
Changes and %changes in gastrin and HbA1c after 6 months from baseline	—

Secondary

Measure	Time frame
Changes and %changes in the following parameters during the observation period Body weight Fasting plasma glucose Office blood pressure Serum creatinine HDL TG LDL	—

Countries

Japan

Contacts

Public ContactInoue Syuji/Eguthi Sizuka

National Hospital Organization National Kochi Hospital, Kochi, Japan Division of Gastroenterology

inouesh@kochi2.hosp.go.jp088-844-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026